GWT1 Antibody

What is GWT1 and what is its function in cellular biology?

GWT1 is an essential enzyme in the glycosylphosphatidylinositol (GPI) biosynthesis pathway. Specifically, it functions as an acyltransferase that catalyzes the palmitoylation of glucosamine phosphatidylinositol (GlcN-PI) at the 2-position of the inositol ring using palmitoyl-CoA as the donor substrate . This acylation step is critical for the subsequent modifications in the GPI anchor pathway. The modifications catalyzed by GWT1 are important for the forward transport and recognition by other enzymes in the pathway . GWT1 is localized to the endoplasmic reticulum membrane and contains multiple transmembrane domains, with recent cryo-EM studies revealing a unique fold with 13 transmembrane helices .

How is GWT1 structurally organized and what domains are critical for its function?

Recent cryo-EM structural studies have revealed that GWT1 adopts a unique fold with 13 transmembrane (TM) helices . The enzyme contains a hydrophobic cavity that serves as the binding site for palmitoyl-CoA, which inserts into a chamber formed by TM4, 5, 6, 7, and 12 . Critical functional residues include D145 and K155, located on the loop between TM4 and TM5, which are believed to bind to the GPI precursor and contribute to substrate recognition and catalysis, respectively . The specificity of GWT1 is determined by these structural features, which provide a basis for understanding how inhibitors like manogepix can selectively target fungal GWT1 while sparing human orthologs.

Why is GWT1 considered a promising target for antifungal drug development?

GWT1 is considered an excellent antifungal drug target for several compelling reasons. First, it is essential for growth in yeast, making its inhibition lethal to fungal cells . Second, the GPI biosynthesis pathway is critical for cell wall integrity in fungi, and disruption of this pathway leads to significant cellular defects. Third, GWT1 inhibitors have demonstrated potent antifungal activity against a broad spectrum of fungal pathogens, including Candida albicans . Fourth, there appears to be sufficient structural differences between fungal GWT1 and its human ortholog (PIG-W) to achieve selective targeting. For example, the Gwt1 inhibitor G884 showed approximately 10-fold selectivity for the fungal target compared to the human counterpart, which correlates with minimal cytotoxicity against human cell lines . Finally, inhibition of GWT1 not only directly affects fungal growth but also exposes β-(1-3)-glucan on the cell surface, potentially enhancing immune recognition and response to the pathogen .

How does inhibition of GWT1 affect fungal cell wall composition?

Inhibition of GWT1 leads to significant alterations in fungal cell wall composition with important immunological implications. When C. albicans cells are treated with GWT1 inhibitors such as gepinacin, G365, or G884 at sub-MIC levels, they exhibit elevated surface exposure of β-(1-3)-glucan, which is normally masked by cell surface GPI-anchored mannoproteins . This exposure occurs because inhibiting GWT1 disrupts the GPI anchor pathway, reducing the presence of GPI-anchored proteins in the cell wall that typically shield β-glucan from immune recognition. Importantly, this effect is specific to GPI pathway inhibition and not simply a consequence of cell death, as demonstrated by the lack of β-(1-3)-glucan exposure when cells are treated with fluconazole . The exposed β-(1-3)-glucan serves as a pathogen-associated molecular pattern (PAMP) that can be recognized by host immune receptors, potentially enhancing the immune response to fungal infections.

What mechanisms explain the chemical synergy observed between GWT1 and MCD4 inhibitors?

The strong chemical synergy observed between GWT1 and MCD4 inhibitors mirrors the synthetic lethality demonstrated when combining conditional mutants of GWT1 and MCD4 . This synergy can be explained by their complementary roles in the GPI biosynthesis pathway. GWT1 catalyzes the acylation of GlcN-PI, while MCD4 is a phosphoethanolamine transferase responsible for adding phosphoethanolamine to C-2 of the first mannose (Man1) of the GPI precursor . These modifications are essential for proper GPI anchor synthesis and attachment to proteins.

When both enzymes are inhibited simultaneously, the GPI pathway is disrupted at multiple points, creating a more severe defect than inhibition at either point alone. This dual inhibition likely prevents any compensatory mechanisms that might partially rescue function when only one enzyme is inhibited. Additionally, the combination may more effectively deplete the pool of mature GPI anchors available for protein attachment, leading to a more pronounced defect in cell wall integrity. This synergistic effect suggests that combination therapies targeting different steps in the GPI pathway could be a powerful strategy for antifungal treatment, potentially allowing for lower doses of each individual inhibitor while maintaining or enhancing efficacy.

How do resistance mutations in GWT1 provide insights into inhibitor binding mechanisms?

Analysis of resistance mutations in GWT1 has provided valuable insights into inhibitor binding mechanisms and drug specificity. Whole genome next-generation sequencing of independently derived drug-resistant mutants to the GWT1 inhibitor G884 revealed amino acid substitution mutations corresponding to Gwt1-G132W or Gwt1-F238C . These mutations were causal for the observed drug resistance phenotype, as no additional nonsynonymous mutations were identified in the genome of two independent G884-resistant isolates .

The Gwt1-G132W mutation maps to the fourth transmembrane domain (TMD), suggesting this region is critical for inhibitor binding . Similarly, recent cryo-EM structural analysis of GWT1 bound to the inhibitor manogepix revealed that the drug occupies the hydrophobic cavity of the palmitoyl-CoA binding site, suggesting a competitive inhibitory mechanism .

These findings indicate that GWT1 inhibitors likely compete with the natural substrate (palmitoyl-CoA) for binding to the active site, and resistance mutations either directly disrupt inhibitor binding or alter the conformation of the binding pocket in a way that reduces inhibitor affinity while preserving enzyme function. Understanding these resistance mechanisms is crucial for the rational design of next-generation inhibitors that can overcome resistance and maintain efficacy against fungal pathogens.

What is the relationship between GWT1 inhibition and immune activation in fungal infections?

The relationship between GWT1 inhibition and immune activation represents a unique and promising aspect of targeting this enzyme for antifungal therapy. GWT1 inhibition leads to cell wall alterations that specifically expose β-(1-3)-glucan, which is normally masked from immune recognition by cell surface GPI-anchored mannoproteins . This exposure triggers immune recognition and response.

Studies have demonstrated that treating C. albicans with GWT1 inhibitors (G365 and G884) leads to significant increases (2-2.5-fold) in secreted TNFα by mouse macrophages co-incubated with the treated fungal cells . This immune-stimulating effect is not observed with other antifungal agents like fluconazole, confirming that it is specifically related to GPI pathway inhibition rather than general fungal cell damage or death .

How does the structural basis of GWT1 selectivity inform the development of species-specific inhibitors?

The structural basis of GWT1 selectivity is crucial for developing inhibitors that target fungal GWT1 while sparing its human ortholog, PIG-W. Cryo-EM structures of yeast GWT1 bound to substrate (palmitoyl-CoA) and inhibitor (manogepix) at 3.3 Å and 3.5 Å resolution, respectively, have provided key insights into this selectivity .

GWT1 adopts a unique fold with 13 transmembrane helices, with palmitoyl-CoA inserting into a chamber formed by TM4, 5, 6, 7, and 12 . The antifungal drug manogepix occupies the hydrophobic cavity of the palmitoyl-CoA binding site, suggesting a competitive inhibitory mechanism . Structural analysis of resistance mutations has elucidated the molecular basis for drug specificity and selectivity .

For example, inhibitors like G884 display appreciable (>10-fold) selectivity for fungal GWT1 versus the human counterpart, consistent with minimal cytotoxicity observed against multiple human cell lines (IC50 > 100 μM) . These structural differences can be exploited to design inhibitors that maximize interactions with fungal-specific regions of the binding pocket while minimizing interactions with conserved regions shared with human PIG-W. Understanding the precise structural determinants of selectivity will enable rational drug design approaches to develop new GWT1 inhibitors with enhanced species specificity, potentially leading to safer and more effective antifungal therapeutics.

What are the optimal assays for evaluating GWT1 inhibition in drug discovery programs?

For effective evaluation of GWT1 inhibition in drug discovery programs, several complementary assays should be employed. The primary assay for direct assessment of GWT1 enzymatic inhibition is an in vitro cell-free system that measures the acylation of GlcN-PI following drug treatment . This assay provides a direct measure of target engagement and can be used to determine IC50 values for potential inhibitors. When implementing this assay, researchers should include appropriate positive controls (such as gepinacin) and negative controls to validate assay performance .

A complementary approach is the Candida albicans fitness test (CaFT), a chemical genomics-based screening platform that can identify potential GWT1 inhibitors based on their effects on heterozygous deletion mutants . In this assay, compounds that inhibit GWT1 will show selective growth inhibition of GWT1 heterozygotes compared to wild-type strains.

Whole-cell antifungal activity should be assessed using minimum inhibitory concentration (MIC) determinations against relevant fungal pathogens, including drug-resistant clinical isolates. Additionally, species selectivity can be evaluated using a complementation assay in which a gwt1Δ strain expresses either fungal Gwt1 or the human ortholog PIG-W . This assay allows for direct comparison of inhibitor effects on fungal versus human enzymes.

Finally, immunostaining and immunofluorescence microscopy can be used to assess the exposure of β-(1-3)-glucan following treatment with GWT1 inhibitors, providing insights into the downstream effects of GWT1 inhibition on cell wall composition .

How can researchers effectively generate and characterize GWT1 inhibitor-resistant mutants?

Generating and characterizing GWT1 inhibitor-resistant mutants is a valuable approach for validating target engagement and understanding resistance mechanisms. Based on successful approaches documented in the literature, the following methodology is recommended:

• Mutant Generation: Start with a haploid yeast strain (e.g., S. cerevisiae) and plate cells on media containing the GWT1 inhibitor at concentrations ranging from 2-8× the MIC. This selection pressure will favor the growth of spontaneous resistant mutants . Alternatively, use chemical mutagenesis (e.g., with ethyl methanesulfonate) to increase mutation frequency before selection.

• Resistance Confirmation: Isolate independent colonies and confirm resistance by determining the MIC of the inhibitor against each isolate compared to the parental wild-type strain. True resistant mutants should show a significant increase in MIC (e.g., ≥4-fold) .

• Cross-Resistance Testing: Test the resistant mutants against other GWT1 inhibitors and unrelated antifungal agents to determine if the resistance is specific to the selecting agent or confers broader resistance.

• Genetic Analysis: Perform whole genome next-generation sequencing (NGS) of multiple independently derived resistant isolates to identify recurring mutations . This approach has successfully identified causal mutations in GWT1, such as Gwt1-G132W and Gwt1-F238C in G884-resistant isolates .

• Mutation Validation: Confirm that identified mutations are causal for resistance by introducing them into a wild-type strain using site-directed mutagenesis and demonstrating that they confer resistance.

• Structural Mapping: Map resistance mutations onto the GWT1 structure to gain insights into inhibitor binding modes and potential mechanisms of resistance .

• Biochemical Characterization: Express and purify the mutant enzymes to evaluate changes in catalytic activity and inhibitor binding affinity compared to wild-type enzyme.

This comprehensive approach not only validates GWT1 as the target of the inhibitor but also provides valuable information for the design of next-generation inhibitors that might overcome resistance mechanisms.

What methods are most effective for studying the immunomodulatory effects of GWT1 inhibition?

To effectively study the immunomodulatory effects of GWT1 inhibition, researchers should employ a multi-faceted approach combining both in vitro and in vivo methods:

• β-Glucan Exposure Analysis:

  • Immunostaining and immunofluorescence microscopy using anti-β-(1-3)-glucan antibodies to detect and quantify the exposure of β-glucan on the fungal cell surface following treatment with GWT1 inhibitors .

  • Flow cytometry with fluorescently-labeled anti-β-glucan antibodies for quantitative assessment of β-glucan exposure across fungal populations.

• Macrophage Activation Assays:

  • Co-incubation of mouse or human macrophages with GWT1 inhibitor-treated fungi, followed by measurement of pro-inflammatory cytokine secretion (particularly TNFα) by ELISA .

  • Analysis of macrophage phagocytic activity against treated versus untreated fungi using fluorescence microscopy or flow cytometry.

• Dendritic Cell Response:

  • Assessment of dendritic cell maturation markers (CD80, CD86, MHC-II) following exposure to GWT1 inhibitor-treated fungi.

  • Measurement of cytokine production profiles, particularly IL-12, which drives Th1 responses.

• T Cell Activation Studies:

  • Analysis of T cell proliferation and differentiation in response to antigen-presenting cells exposed to GWT1 inhibitor-treated fungi.

  • Characterization of T helper cell polarization (Th1/Th2/Th17) following exposure.

• In Vivo Immune Response Assessment:

  • Evaluation of cytokine profiles in serum and infected tissues of animal models treated with GWT1 inhibitors.

  • Histopathological analysis of infected tissues to assess immune cell recruitment and fungal clearance.

  • Adoptive transfer experiments to determine the specific immune cell populations responsible for enhanced clearance.

• Combination Studies:

  • Analysis of potential synergistic immunomodulatory effects when GWT1 inhibitors are combined with other antifungal agents or immunomodulatory drugs.

When conducting these studies, it is critical to include appropriate controls, such as heat-killed fungi, fungi treated with other classes of antifungals (e.g., fluconazole), and untreated fungi, to distinguish the specific immunomodulatory effects of GWT1 inhibition from general effects of fungal growth inhibition or cell death .

How is GWT1 research contributing to antimalarial drug development?

GWT1 research has unexpectedly contributed to advances in antimalarial drug development, demonstrating the value of cross-disease research approaches. Initially identified as a target for antifungal development, GWT1 inhibitors were subsequently found to show promising antimalarial activity . This discovery emerged from collaborative research between Eisai and Japan's National Institute of Advanced Industrial Science and Technology (AIST), which revealed that GWT1 protein is an enzyme catalyzing acyl group transfer reaction in the glycosylphosphatidylinositol (GPI) biosynthesis pathway .

The transition from antifungal to antimalarial research was facilitated by joint research with the Research Institute for Microbial Diseases at Osaka University, which demonstrated that some GWT1-targeting antifungal candidates showed antimalarial activity, likely through similar mechanisms targeting the GPI biosynthesis pathway in malaria parasites . This discovery led to a partnership with Medicines for Malaria Venture (MMV) in 2012, which successfully identified lead compounds and initiated lead optimization to create candidate compounds for antimalarial therapy .

This cross-disciplinary application highlights the value of target-based approaches in drug discovery and demonstrates how research in one therapeutic area can unexpectedly benefit another. The GPI biosynthesis pathway appears to be a vulnerable target in multiple pathogens, and understanding the structural and functional characteristics of key enzymes like GWT1 can inform drug development across different disease areas.

What comparative insights does structural analysis of GWT1 provide across species?

Structural analysis of GWT1 across different species provides valuable comparative insights that inform both basic biology and drug development strategies. The recent cryo-EM structures of yeast GWT1 bound to both substrate (palmitoyl-CoA) and inhibitor (manogepix) at high resolution (3.3 Å and 3.5 Å, respectively) have revealed that GWT1 adopts a unique fold with 13 transmembrane helices . This structural information allows for comparative analysis between fungal GWT1 and its orthologs in other organisms, including the human ortholog PIG-W and potential homologs in parasites like Plasmodium.

Key comparative insights include:

• Substrate Binding Pocket: The palmitoyl-CoA binding chamber is formed by transmembrane helices 4, 5, 6, 7, and 12 in yeast GWT1 . Comparative analysis of these regions across species can reveal conservation patterns and species-specific features that might be exploited for selective inhibitor design.

• Catalytic Residues: The crucial residues D145 and K155, located on the loop between TM4 and TM5, are believed to bind to the GPI precursor and contribute to substrate recognition and catalysis . Assessing the conservation of these residues across species helps understand functional conservation and divergence.

• Inhibitor Selectivity: Structural analysis of resistance mutations and inhibitor binding sites explains the observed selectivity of compounds like G884, which shows approximately 10-fold higher affinity for fungal GWT1 compared to human PIG-W . These structural differences can guide the development of species-selective inhibitors.

• Evolutionary Conservation: Comparing GWT1 structures across evolutionary distance provides insights into which structural features are essential for function and which have diverged, potentially informing both our understanding of GPI biosynthesis evolution and drug design strategies.

These comparative structural insights have practical applications in developing selective inhibitors that target pathogen GWT1 while sparing the human ortholog, and in understanding how structural variations contribute to functional differences across species.